1. Outcomes After Transfemoral Transcatheter Aortic Valve Implantation With a SAPIEN 3 Valve in Patients With Cirrhosis of the Liver (a Tertiary Care Center Experience)
- Author
-
Sanchit Chawla, Maan Fares, Cristiano Quintini, K. V. Narayanan Menon, Shashank Shekhar, James Yun, Amar Krishnaswamy, Grant W. Reed, Rama Dilip Gajulapalli, Serge C. Harb, Hassan Mehmood Lak, Raunak Nair, Adil Vural, Daniel J.P. Burns, Mohamed M. Gad, Samir R. Kapadia, Rishi Puri, and Beni R Verma
- Subjects
Liver Cirrhosis ,Male ,Pacemaker, Artificial ,medicine.medical_specialty ,Hepatorenal Syndrome ,Cirrhosis ,Transcatheter aortic ,Myocardial Infarction ,Severity of Illness Index ,Tertiary care ,Tertiary Care Centers ,Transcatheter Aortic Valve Replacement ,Postoperative Complications ,Internal medicine ,medicine ,Humans ,In patient ,Mortality ,Symptomatic aortic stenosis ,Aged ,Retrospective Studies ,Aged, 80 and over ,Heart Failure ,business.industry ,Cardiac Pacing, Artificial ,Aortic Valve Stenosis ,medicine.disease ,Readmission rate ,Femoral Artery ,Heart Block ,Treatment Outcome ,Case-Control Studies ,Concomitant ,Heart failure ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Little is known about the utility of transcatheter aortic valve implantation (TAVI) in patients with cirrhosis of the liver, and their outcomes have not been studied extensively in literature. We performed a retrospective analysis of patients with severe symptomatic aortic stenosis (AS) who underwent transfemoral TAVI with a SAPIEN 3 valve at our institution between April 2015 and December 2018. We identified 32 consecutive patients with evidence of cirrhosis of the liver on imaging (including ultrasound and/or computed tomography) and patients with severe symptomatic AS who underwent transfemoral TAVI with a SAPIEN 3 valve. Among 1,028 patients, 32 had cirrhosis of the liver and 996 constituted the control group without cirrhosis. Mean age in the cirrhosis group was 74.5 years compared with 81.2 years in the control group. Baseline variables were comparable between the groups. Compared with the noncirrhotic group, patients with cirrhosis had a similar 1-year mortality (12% vs 12%, p = 1), a lower 30-day new pacemaker after TAVI rate (6% vs 9%, p = 0.85), a higher 30-day and 1-year readmission rate for heart failure (11% vs 1% and 12% vs 5%, p = 0.12, respectively), and a similar 1-year major adverse cardiac and cerebrovascular event rate (15% vs 14%, p = 0.98). In conclusion, patients with severe AS with concomitant liver cirrhosis who underwent TAVI demonstrated comparable outcomes to their noncirrhotic counterparts.
- Published
- 2021